Marksans Pharma has announced its financial results for the second quarter and first half of the fiscal year 2027. The company demonstrated robust growth, with a 30.5% year-on-year increase in revenue for Q2 FY27, reaching ₹940.2 crore. For the half-year ended September 30, 2026 (H1FY27), revenue grew by 32.9% to ₹1,781.0 crore. Profit after tax (PAT) also saw substantial increases, up 44.8% for Q2 FY27 and 92.5% for H1FY27, reflecting strong operational performance and strategic execution across key markets.
Marksans Pharma Announces Strong Q2 and H1 FY27 Financials
Marksans Pharma has reported a significant upswing in its financial performance for the second quarter and the first half of the fiscal year 2027. The company showcased impressive year-on-year growth across key financial metrics, highlighting its expanding market presence and operational efficiency.
Q2 FY27 Performance Highlights
In the second quarter of FY27, Marksans Pharma achieved a record revenue of ₹940.2 crore, marking a substantial 30.5% increase compared to the same period last year. This growth was driven by strong performances in its core markets, particularly UK & Europe, which contributed ₹159 crore to the total revenue increase. The US market also showed strength, adding ₹34 crore. Excluding the impact of acquisitions, organic revenue remained robust, growing by approximately 25% year-on-year.
EBITDA for Q2 FY27 saw a remarkable increase of 48.3% year-on-year, reaching ₹214.3 crore. The EBITDA margin expanded by 274 basis points to 22.8%, demonstrating improved profitability. Profit After Tax (PAT) grew by 44.8% year-on-year to ₹143.5 crore, with the net profit margin improving to 15.0%.
H1 FY27 Performance Highlights
For the first half of FY27 (H1FY27), Marksans Pharma reported total income of ₹1,824.5 crore, a 33.4% increase over H1FY26. Operating revenue grew by 32.9% to ₹1,781.0 crore. Gross profit rose by 36.0% to ₹1,047.4 crore, with the gross margin expanding to 58.8%. EBITDA surged by 74.7% to ₹427.3 crore, and the EBITDA margin improved significantly to 24.0% (up 574 bps). PAT for H1FY27 nearly doubled, growing by 92.5% to ₹302.9 crore, with the net profit margin strengthening to 16.6%.
The company also highlighted strong cash generation, with operating cash flow reaching ₹322 crore and free cash flow at ₹275 crore in H1FY27. The cash balance stood at a healthy ₹1,124 crore as of September 30, 2026.
Geographical Performance
Revenue by geography showed significant growth in key regions. UK & Europe revenue grew by 65% year-on-year to ₹405 crore in Q2FY27. Australia & New Zealand also saw strong traction, with revenue up 64.0% year-on-year to ₹101 crore. US & North America revenue reached ₹421 crore, an increase of 8.7% year-on-year. The Rest of World segment revenue declined by 47.0% year-on-year to ₹14 crore.
The management commentary emphasized a landmark quarter for Marksans Pharma, delivering its strongest-ever performance. The company is confident in its growth trajectory, driven by a global footprint, a robust product pipeline, and a strong net-cash position.
Source: BSE
